Shanghai Pulmonary Hospital (Shanghai Pulmonary Hospital Affiliated to Tongji University)

It relies on the National Key Clinical Specialty of Thoracic Surgery and the Shanghai Lung Transplantation Engineering Technology Research Center; it is one of the earliest centers in China to carry out clinical research on lung transplantation, and the only transplant center in China that can perform all types of lung transplantation surgery; it has established a complete MDT system for end-stage lung disease preoperative assessment, donor lung repair, transplantation surgery, perioperative ECMO support, and long-term anti-rejection follow-up; and it benchmarks itself against the Lung Transplantation Center of Toronto General Hospital in Canada.

It is affiliated with the National Key Clinical Specialty of Thoracic Surgery and the Shanghai Lung Transplantation Engineering Technology Research Center; one of the earliest lung transplant centers in China, with the largest lung transplant volume in Shanghai; the only transplant center in China capable of performing all lung transplant procedures; a national-level referral platform for end-stage lung diseases; and benchmarked against top international lung transplant centers (Lung Transplant Center of Toronto General Hospital, Canada, and Cleveland Clinic, USA).

Historical Origins and Spiritual Inheritance:

The Pulmonary Hospital initiated animal experiments on lung transplantation in 1978; completed its first clinical lung transplant in 2003; and, through the continuous efforts of three generations of academic leaders—Ding Jia'an, Jiang Gening, and Chen Chang—and upholding the hospital motto of "high moral character, excellent medical skills, and saving lives," has overcome core challenges such as lung transplantation infection, ischemia-reperfusion injury, and acute and chronic rejection, achieving landmark results such as Asia's first lung retransplantation and China's first living donor lung lobe transplantation.

Core business operational efficiency:

The hospital has established an independent lung transplant ward and a dedicated transplant ICU; it performs approximately 40-50 lung transplants annually, with a cumulative total of over 300; it accounts for more than 80% of Shanghai's lung transplant surgeries; its surgical success rate is >99%, and its 5-year postoperative survival rate is higher than the national average and close to international advanced levels; it has established a complete multidisciplinary team (MDT) system encompassing donor lung assessment, organ transport, transplant surgery, perioperative ECMO/CRRT support, and postoperative immunosuppression and lifelong follow-up; it undertakes all types of end-stage lung disease patients awaiting transplantation, post-transplant complications, and referrals for re-lung transplantation from across the country.

Core Advantages: The only domestic company to fully cover all lung transplant procedures; the first in China to perform EVLP ex vivo donor lung repair, ECMO bridging lung transplantation, and cross-hospital ECMO patient transfer and transplantation; independently developed a portable constant-temperature donor lung transport system to extend the preservation time of donor lungs; the MDT team includes a fixed multidisciplinary team of thoracic surgery, respiratory critical care, pulmonary circulation, anesthesia, imaging, pathology, infectious diseases, and transplant immunology. Discipline Positioning and Global Benchmarking: A domestic center for clinical diagnosis, quality control, and translational medicine in lung transplantation for end-stage lung disease; benchmarking against the Lung Transplant Center at Toronto General Hospital in Canada; differentiating itself from overseas centers by focusing on basic immunology research, while pulmonology lung transplantation emphasizes stratification of lung transplantation indications for end-stage lung disease in the Chinese population, EVLP repair of marginal donor lungs, ECMO bridging transplantation for critically ill patients, and integrated prevention and control programs for post-transplant rejection and infection.

A national key clinical specialty; ranked 2nd nationally in thoracic surgery according to Fudan University's specialty reputation list; the world's largest single-center general thoracic surgery center in terms of surgical volume; an international training base for minimally invasive thoracic surgery; a domestic benchmark for lung transplantation, complex tracheal surgery, and minimally invasive diagnosis and treatment of early-stage lung cancer; and a multidisciplinary team (MDT) for lung cancer, tracheomedial tumors, and end-stage lung disease. Integrated diagnosis and treatment system; benchmarked against the Royal Brompton Thoracic Centre in the UK ; a "National Key Clinical Specialty" and "Shanghai Lung Transplantation Engineering Technology Research Center"; ranked 2nd in the national thoracic surgery category in Fudan University's specialty reputation list; the world's largest single-center general thoracic surgery center in terms of surgical volume; an international training base for minimally invasive thoracic surgery; specializing in lung cancer surgery, complex tracheal surgery, lung transplantation, and mediastinal chest wall surgery. The Department of Thoracic Surgery at Shanghai Pulmonary Hospital was founded in 1953, growing alongside the hospital (formerly Chengzhong Sanatorium, founded in 1933, the first municipal tuberculosis prevention and treatment hospital), evolving from a designated tuberculosis hospital primarily focusing on pulmonary tuberculosis to one of the best thoracic surgery centers in the country. Professor Ding Jia'an, the discipline's founder, has worked at the hospital since 1961 and is a leading expert in thoracic surgery in China, particularly in lung... He possesses profound expertise in tracheal, mediastinal, and esophageal surgery: In 1978, he pioneered animal experiments with lung transplantation; in 1993, he developed a NiTi memory alloy stent for treating severe tracheal stenosis and obtained a national patent; in 1995, he was the first in China to perform lung volume reduction surgery to treat severe obstructive emphysema; and in 2000, he was the first to successfully treat an elderly patient using a thoracic bypass pump. (Ding Jia'an) With 57 years of medical experience, Dr. [Name] has published 217 papers and edited or co-edited 6 monographs. In 2017, he was awarded the "Outstanding Contribution Award for Thoracic and Cardiovascular Surgery in China" (one of only four people nationwide to receive this honor). Inheriting the spirit of "striving for excellence and daring to be a pioneer," and through several generations of academic leaders including Ding Jia'an, Jiang Gening, and Chen Chang, the department has developed into the world's largest general thoracic surgery center in terms of surgical volume.

Core business operational efficiency:

The department is currently a national key clinical specialty, a key discipline in Shanghai, and a "top priority" key discipline in Shanghai. To date, it has performed over 100,000 thoracic surgeries. It has 8 general wards, 2 special needs wards, and 2 intensive care units, with a total of 525 beds and 26 high-standard thoracic surgery operating rooms equipped with advanced equipment such as intraoperative CT scanners, intraoperative C-arm machines, and the da Vinci surgical robot. It is the host institution of the Shanghai Lung Transplantation Engineering Technology Research Center. In 2021, the department performed over 21,000 surgeries, making it the world's largest general thoracic surgery center in terms of surgical volume, and ranking first internationally in minimally invasive surgeries. Currently, the hospital has 28 associate chief physicians or above, 15 professors and associate professors, 11 doctoral supervisors and 12 master's supervisors. Among them are 2 recipients of the National Natural Science Foundation of China (NSFC) Outstanding Youth Fund, 2 recipients of the NSFC Excellent Youth Fund, 1 chief scientist of the Ministry of Science and Technology's Major Research and Development Program, 1 chief young scientist of the 973 Program, 2 members of the American Association for Thoracic and Cardiovascular Surgery (AATS), and 2 Fellows of the Royal College of Surgeons of the United Kingdom.

Discipline Positioning and Core Strengths:

For many consecutive years, the department has ranked among the top three in the Fudan University's "China's Best Hospital Specialty Reputation Ranking" for general thoracic surgery. In 2022, it ranked second in the national comprehensive ranking of thoracic surgery (reputation standardized value of 66.67 points, comprehensive score of 86.67 points). Its STEM (Science, Technology, Engineering, and Mathematics) evaluation of Chinese hospitals has consistently ranked among the top three in the country in recent years. From 2017 to 2022, it ranked first in the national hospital internet influence ranking for thoracic surgery. Its core advantages can be summarized as a four-dimensional integration: "World's largest general thoracic surgery center with the highest surgical volume × International training base and global standard setter for single-port thoracoscopic surgery × Most innovative tracheal surgery techniques in China × Comprehensive lung transplantation system." The department is a training base for core thoracic surgeons of the European Association of Thoracic and Cardiovascular Surgery, a recommended unit for "single-port thoracoscopic training" of the European Association of Thoracic Surgeons, and the preferred training base for single-port thoracoscopic surgery of the Japan Respiratory Society. It has received 830 international senior physicians from Europe, America, Asia, and Africa for further training. Former presidents of the European Association of Thoracic and Cardiovascular Surgery, the International Society for Minimally Invasive Surgery, the World Association for Lung Cancer Research, and the Japan Respiratory Society have all come to the hospital to study or provide guidance. The department is characterized by ultra-large single-port minimally invasive procedures, complex tracheal surgery, lung transplantation, and global thoracic surgeon training.